Expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder

Abstract

The expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder (TCCB) and its clinical significance were investigated. Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlation between the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathologic factors was statistically analyzed. The results showed that the positive rate of KAI1/CD82 and MRP-1/CD9 in TCCB was 50% and 61.5%, respectively. The MRP-1/CD9 and KAI1/CD82 expression was significantly associated with grade of TCCB (P<0.05), but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB (P>0.05). The expression level of MRP-1/CD9 and KAI1/CD82 in recurrent TCCB samples was lower than that in non-recurrent samples (P<0.05). Meanwhile, the correlation between the KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant (r=0.316, P<0.05). It was concluded that KAI1/CD82 and MRP-1/CD9 expression may be important prognostic indicators and potentially useful for assessing the biological behavior of TCCB.

Keywords

bladder carcinoma / transitional cell / KAI1/CD82 / MRP-1/CD9 / immunohistochemistry

References

[1] DongJ. T., LambP. W., Rinker-SchaefferC. W., et al.. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (Washington DC), 1995, 268: 884-886

[2] JeanM.. New clue to prostate cancer spread. Science, 1995, 268: 799-800

[3] MiyakeM., KoyamaM., SenoM., et al.. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med, 1991, 174(12): 1347-1354

[4] OnoM., HandaK., DonaldA., et al.. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res, 1999, 59: 2335-2339

[5] AdachiM., TakiT., KonishiT., et al.. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol, 1998, 16: 1397-1406

[6] FriessH., GuoX. Z., BerberatP., et al.. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer, 1998, 79: 349-355

[7] YangX., WeiL., TangC., et al.. KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res, 2000, 6: 3424-3429

[8] JacksonP., KingsleyE. A., RussellP. J., et al.. Inverse correlation between KAI1 mRNA levels and invasive behavior in bladder cancer cell lines. Cancer Lett, 2000, 156(1): 9-17

[9] MhawechP., HerrmannF., CoassinM., et al.. Motility-related protein (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer, 2003, 98(10): 1649-1657

[10] MiyakeM., NakanoK., ItoiS., et al.. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res, 1996, 56: 1244-1249